The Government Shutdown Won't Stop This FDA Meeting
Oct 6th 2013 10:15PM
Updated Nov 6th 2013 10:12PM
We may be in the midst of one of the biggest biotech bull markets in history, but shares of controversial biotech company Amarin have plunged more than 40% in the past 12 months. A number of issues have pressured shares, ranging from question marks over the market exclusivity of the company's fish-oil drug Vascepa to emerging generic competition. Despite this drop, Amarin has the opportunity to prove the naysayers wrong this month during an FDA advisory committee meeting that may recommend expanded approval for Vascepa.
The company announced last week that the government shutdown wouldn't change the date of this meeting, so investors should be prepared for this major catalyst. In the following video, analysts David Williamson and Max Macaluso discuss the significance of this meeting to Amarin's business and also examine competition from GlaxoSmithKline's Lovaza and AstraZeneca's experimental fish-oil pill, Epanova.
One incredible stock for growth investors
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!
The article The Government Shutdown Won't Stop This FDA Meeting originally appeared on Fool.com.David Williamson owns shares of Amarin and Facebook. Max Macaluso, Ph.D. owns shares of Apple. The Motley Fool recommends and owns shares of Amazon.com, Apple, Facebook, and Google. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.